Drug Type siRNA |
Synonyms QPI 1007, QPI-1007, RBD 1007 + [4] |
Target |
Mechanism caspase 2 inhibitors(Caspase-2 inhibitors), Gene expression inhibitors, RNA interference |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Optic Neuropathy, Ischemic | Phase 3 | US | 24 Feb 2016 | |
Optic Neuropathy, Ischemic | Phase 3 | CN | 24 Feb 2016 | |
Optic Neuropathy, Ischemic | Phase 3 | AU | 24 Feb 2016 | |
Optic Neuropathy, Ischemic | Phase 3 | DE | 24 Feb 2016 | |
Optic Neuropathy, Ischemic | Phase 3 | IN | 24 Feb 2016 | |
Optic Neuropathy, Ischemic | Phase 3 | IL | 24 Feb 2016 | |
Optic Neuropathy, Ischemic | Phase 3 | IT | 24 Feb 2016 | |
Optic Neuropathy, Ischemic | Phase 3 | SG | 24 Feb 2016 | |
Optic Nerve Injuries | Phase 3 | - | - | |
Optic Nerve Injuries | Phase 3 | - | - |
Phase 1 | 48 | dxncsikrzq(iflgrrbmcu) = n=11 poohprxrvt (itxpfbepxg ) View more | - | 01 Jun 2013 |